Treatment response to pregabalin in fibromyalgia pain: Effect of patient baseline characteristics

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 14, 2010, Pages 2275-2280

  Emir, Birol ^a   Murphy, Thomas Kevin ^a   Petersel, Danielle Lauren ^a   Whalen, Ed ^a  

^a PFIZER INC   (United States)

Author keywords

Chronic pain; Fibromyalgia; Pregabalin; Treatment response

Indexed keywords

PREGABALIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS; ANXIETY; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 77956570286     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.509717     Document Type: Article

References (28)

1. Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009;10:777-791
2. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8:177-189
3. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008;4:1059-1071
4. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006;8:208
5. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726-734
6. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Rev Rheumatol 2006;2:90-98 (Pubitemid 43239208)
7. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/ fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-556
8. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82
9. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006;103:17537-17542
10. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-150
11. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
12. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-1273
13. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514
14. Kim L, Lipton S, Deodhar A. Pregabalin for fibromyalgia: some relief but no cure. Cleve Clin J Med 2009;76:255-261
15. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706-715
16. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172
17. Pauer L, Danneskiold-Samsoe B, Jespersen A, et al. Barret pregabalin for management of fibromyalgia (FM): a 14-week, randomized, double-blind, placebo-controlled, monotherapy trial. Ann Rheum Dis 2008;67:256
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370
19. Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 2009;29:4076-4088
20. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 2008;105:3628-3633
21. Takasu K, Honda M, Ono H, Tanabe M. Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury. Br J Pharmacol 2006;148:233-244
22. Takeuchi Y, Takasu K, Honda M, et al. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur J Pharmacol 2007;556:69-74
23. Tanabe M, Takasu K, Kasuya N, et al. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 2005;144:703-714
24. Kubota T, Fang J, Meltzer LT, Krueger JM. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther 2001;299:1095-1105
25. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28:187-193
26. Bliwise DL. Sleep in normal aging and dementia. Sleep 1993;16:40-81
27. Edwards RR, Haythornthwaite JA, Tella P, et al. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 2006;104:1243-1248
28. Kalso E, Simpson KH, Slappendel R, et al. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39